Bey R F, Larson M E, Lowery D E, Lee B W, Knutson K S, Simonson R R, King V L
Department of Veterinary PathoBiology, College of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA.
Infect Immun. 1995 Aug;63(8):3213-17. doi: 10.1128/iai.63.8.3213-3217.1995.
A 110-kDa Borrelia burgdorferi fusion protein, Escherichia coli expressing the fusion protein, transformed E. coli lacking the fusion protein insert, and lyophilized whole B. burgdorferi bacteria were compared for immunogenicity in C3H/He mice. Immunized mice were challenged with a variety of isolates from the United States or the European isolate P/Gau 3 weeks following the last inoculation. An average of 76.7% of the mice immunized with 25 micrograms of lyophilized whole B. burgdorferi cells were protected from infection, while 60% of the mice immunized with the 110-kDa fusion protein were protected. Whole E. coli bacteria expressing the fusion protein protected 57.7% of immunized mice against experimental challenge. Lower levels of protection occurred in mice challenged with the European isolate than in those challenged with isolates originating from the United States. These results demonstrate the potential of the 110-kDa fusion protein for use as a component of a subunit vaccine for prevention of Lyme borreliosis.
对一种110千道尔顿的伯氏疏螺旋体融合蛋白、表达该融合蛋白的大肠杆菌、缺乏融合蛋白插入片段的转化大肠杆菌以及冻干的完整伯氏疏螺旋体细菌在C3H/He小鼠中的免疫原性进行了比较。在最后一次接种后3周,用来自美国的多种分离株或欧洲分离株P/Gau对免疫小鼠进行攻击。平均而言,用25微克冻干的完整伯氏疏螺旋体细胞免疫的小鼠中有76.7%受到感染保护,而用110千道尔顿融合蛋白免疫的小鼠中有60%受到保护。表达融合蛋白的完整大肠杆菌保护了57.7%的免疫小鼠免受实验性攻击。用欧洲分离株攻击的小鼠的保护水平低于用源自美国的分离株攻击的小鼠。这些结果证明了110千道尔顿融合蛋白作为预防莱姆病疏螺旋体病亚单位疫苗成分的潜力。